												-	7
-			de this box -						Patent	and Trade	Approved for use throug ernark Office: U.S. DEF	PTO/6 h 10/31/99. Ch PARTMENT DE	EDBA (10 19 065 HO COMMED
Under the I	Paperwor	k Reductio	n Act of 1995	, no persons an	e required to res	pond to a collection	of information unte	255 il c	contains a valid OM	B control	number	~	<u>ק</u>
	Subs	titute fo	r form 144	9A/PTO					Co	mplete	if Known	ER 16	A A
PE	STATEMENT I			ATION DISCLOSURE ENT BY APPLICANT many sheets as necessary)			Application Number			09/807,558	ER 1600/2900	2001	
210	שי ש	1					Filing Date				July 17, 2001		
l	Æ.	į					First Named	Inve	intor		Stefan Dietmat	Anker	
		•					Group Art Ur				1614	A INCI	
20		•					Examiner Na	_			1014		
STEEL STEEL	1	1	of		8		Attorney Doc		Number		ICI 102		
							,,		144111001		101 102		
						U.S. PATE	NT DOCUMEN	NTS					
Examiner Initials*				Name of Patentee or Applicant of Cited Document			Date of Cited Pages, C Passage MM-OD-YYYY		ages, Columns, Line Passages or Releva	s, Where Rel nt Figures App	evant . pear		
	<u> </u>	+								†			
													-
	 												
		+											
	1	 		 				<u> </u>		<u> </u>			
	 	\vdash		 						<u> </u>			
								<u> </u>	·	-			
								_					
	ļ								 -	 			
		 											
													
·	 	 -				·							
		 											
													
						OREIGN PAT	ENT DOCUM	FNT	\$				
Examiner Initials*	Cite No. ¹		Foreign I	Patent Docum	nent	Name o	of Patentee or f Cited Documen		Date of Publicat	ion of MM-	Pages, Columns, L Relevant Passages	or Relevant	Te
	Office. Number*			Kind Code ⁵ (if known)	1			DD-YYYY		Figures Appear			
1-14		wo	96/24373		A2	G.D. Searle &	Co.		08-15-1996				+
CH	_	JP	09 071 5	86		Yamanouchi		_	03-18-1997	\dashv			+
	<u> </u>							\dashv		\dashv			+
		<u> </u>						\neg		+			+
													+-
			L		<u> </u>			7	·				+

Date Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

+

Examine

Signature

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

							•					_	
Please (type a	plus sig	on (+) insid	te this box →	. [•	l					7	Orono.	
									Betant and T	Approved for use thin	ough 100	OMB 0651	00
I Indoct	- Don		Dadi sellas	A-4 -4 100E		•			ratent and i	Approved for use the rademark Office: U.S. (DEPARTMENT	OF COMMI	7
0.00.0	e rap	Subst	itute for	form 144!	PA/PTO	ns are required to respond	to a collection of infor	mation unless it contait	ins a valid OMB con	trol number			
1				101111 1446	57-VI 10		į		Complete !		1	2	τ
i							ļ	Complete if Known					Γ
F		IN	FOR	MATIC	N DI	SCLOSURE	Application N	lumber		09/807,558		4	=
7 -	رن.					APPLICANT					ğ	2001	<
	~ ×	./			U.,	AFFLICAN				I	₹	21	Γ
212	m,	2	(use	as many s	sheets a	s necessary)				1	600/2900		Г
		8		-			Filing Date			July 17, 2001			_
1	4	5 /					First Named I	nventor		Stefan Dietmat	Ankor		
8 TRA	OEN						Group Art Un	it		1614	AING!		_
	_						Examiner Nan						_
Sheet	L		2	of	<u></u>	8	Attorney Doci	ket Number		ICI 102			_
						071150 45-							_
Examin	er's T	Cite	т—		laction	de name of the author	NON PATENT LI	TERATURE DO	CUMENTS				_
Initial		No.	1		item (b	de name of the author ook, magazine, jouma	(in CAPITAL LETT)	ERS), title of the ar	rticle (when appn	opriate), title of the			·Z
			41175										
г,			Choct	R & COAT 115:836-8	FS, "Cai	rdiac Cachexia. A :	syndrome with in	npaired survival	and immune a	nd neuroendocrine	e activation	 	
E1	A		0.,03	. 15.050-0	جزر (راغه	55).							
ì	1		ANKE	R & RAUC	CHHAUS	S, "Insights into the	pathogenesis of	chronic heart fa	ilure: immuno	netiuntles and	-1 - 1 - 5		_
·			Opin C	ardiol 14((3):211-	216 (1999).	,		maic. Hillione	GUVAUON AND CA	cnexia," Ca	urr	
	\dashv		ANKE	*Cotool	1								
- 1	- 1		- VAIVE	v, Caleu	ioiamini	e levels and treatm	ent in chronic he	art failure," Eur.	Heart J. 19(Su	ppl F.):56-61 (199	98).		_
		_ 1											
	Т		ANKER	Relatio	n betwe	en serum urice aci	d and lower limb	blood flow in na	tionts with che	onio hond failure !	114-0		_
			(1997).					non in pa	INCING WILL CAN	onic neart failure,"	mean /6:3	39-43	
\dashv	\dashv		ANKED	ot at M	National of or							- 1	
			heart fa	ilure." <i>Fu</i>	ytokine mneen	es and neurohomo Heart Journal 20:6	nes relating to bo	ody composition	alterations in t	he wasting syndro	me of chro	onic	_
	\perp						00-030 (1333).						
T	T	\neg	ANKER	, et al., "I	lormona	al changes and cata	abolic/anabolic in	nbalance in chro	nic heart failur	and their impact			_
		ľ	cachexi	a," Circui	ation 96	:526-534 (1998).			Hour lailui	e end men nubou	ance for ca	iraiac	
\dashv	+	\dashv	ANKED	otal W	400 of t								ĺ
		ľ	MINER (1999).	, c . al., L	uss of E	one mineral in pati	ents with cachex	ia due to chronic	c heart failure,	Am J Cardiol 83:	612-615	_	-
												ĺ	ı
T	T		ANKER	, et al., "T	he influ	ence of muscle ma	ss, strength, fatio	ability and blood	flow on over-	ico canacit : !=	ab = at' =		
		ļ	non-cac	hectic par	tients w	ith chronic heart fai	lure," European I	Heart Journal 18):259-269 (199	ase capacity in ca 7).	cnectic and	¹	
-	+											i	
1	-	ľ	NNEK, I Ameri	, et al., "Ti Coll Cardi	umor ne	ecrosis factor and s 97-1001 (1997).	teroid metabolisr	n in chronic hear	rt failure: Poss	sible relation to mu	scle wasti	ng.*	┨
⅃.		ſ	· - 4.101 \	Jon Jarui	U 30.33	71-1001 (1997),						"	
\mathcal{J}	7	7	NKER,	et al., "To	umour n	necrosis factor alph	a as a predictor of	of impaired pools	log blood 6				╛
V	- 1	[fa	ailure,"	Q. J. Med	. 91:19	9-203 (1998).	(A MINTER DESK	IRB DIDOG IJOM	in patients with c	hronic hea	rt ¯	1

Date Considered

failure," Q. J. Med. 91:199-203 (1998).

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Examiners

Signature

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw fine through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WiPO Standard ST. 18 if possible. ⁶ Applicant to place a check mark here if English language

Please type a plus sign (+) inside this box → + Under the Paperwork Reduction Act of 1995, no persons are required to respond to	n a collection of information, values II seeming a	Approved for use through 10 Patent and Trademark Office: U.S. DEPAR	101ma -	SB/08A (1)MB 0651- F COMME	
Substitute for form 1449A/PTO	o desired in the inguity unless it compans	a valid OMB control number	<u></u>		
	·	Complete if Known	SE SE	SEP	THE STATE OF THE S
INFORMATION DISCLOSURE	Application Number	09/807,558	<u></u>	89	. ہے۔
STATEMENT BY APPLICANT			田田	4	Π
(use as many sheets as necessary)			1600,	200	₹
SEP 21 700 E	Filing Date	July 17, 2001	8		нП
	First Named Inventor	Stefan Dietmat Anker			d
\a. .\$\\delta\	Group Art Unit	1614	<u> </u>		Ť
3 of 8	Examiner Name				\dashv
shall 3 of 8	Attorney Docket Number	ICI 102			\dashv

Examiner's	C:4-	OTHER ART NON PATENT LITERATURE DOCUMENTS	
Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	1
FH	_	BENEDICT & GRAHAME-SMITH, "Plasma adrenaline and noradrenaline concentrations and dopamine-b-hydroxylase activity in myocardial infarction with and without cardiogenic shock," British Heart Journal 42:214-220 (1979).	
		BERNE, "Effect of epinephrine and norepinephrine on coronary circulation," Circ Res 6:644-655 (1958).	-
		BESARB, et al., "The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epotein," N Eng J Med 339(9):584-590 (1998).	_
		BRINK, et al., "Angiotension II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism," J Clin Invest 97(11):2509-2516 (1996).	_
		CHILAIN, et al., "Adrenergic coronary tone during submaximal exercise in the dog is produced by circulating catecholamines," Cir Res 58:68-82 (1986).	
		CHUA, et al., "Relation between chemosensitivity and the ventilatory response to exercise in chronic heart failure," J Am Coll Cardiol 27:650-657 (1996).	
		COATS, "Symptoms and quality of life in heart failure: the muscle hypothesis," "Symptoms and quality of lifein heart failure: the muscle hypothesis," Br. Heart J 72:S36-S39 (1994).	
		COWIE, et al., "The epidemiology of heart failure," European Heart Journal 18:208-225 (1997).	
 	C	DANERYD, et al., "Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following reatment with recombinant erythropoietin: A randomized prospective study," Cancer Res. 58(23):5374-5379 (1998).	_
V	C	DAVENPORT, "Characteization of [125]-PD164333, an ET _A selective non-peptide radiolabelled antagonists, in normal and iseased human tissues," <i>Br. J Pharmacol</i> 123(2):223-30 (1998).	

Examiner's T		7.4					
Signature	hira	W7	Date Considered	1.	$\sqrt{2}$	1	
				(0)	ニアタバ) <i>/</i>	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+,

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Please type a							Pa	Approved for use itent and Trademark Office: U.	through 10/ S. DEPARTI	PTO16 31/99 OW MENT 97	3/08A (1 IB 06514 DOMME	10-9 003 RC
Under the Pa	Subs	rk Reductio	n Act of 1995,	, no persons a	re required to respond	to a collection of information	unless it contains a valid	OMB control number		\mathcal{Z}	S	
						Complete if Known					₽ 2	_
2001	اا د د	STATE	MENT	ON DISC BY AF	CLOSURE PPLICANT ecessary)	Application Numi	per	09/807,558		1600/290	2001	
1	Š.,				•	Filing Date		July 17, 2001		웅 —		4
ADEMANA S	<i>)</i> *					First Named Inver	ntor	Stefan Dietma	at Ankar			÷
DEAL						Group Art Unit		1614				
						Examiner Name						_
Sheet	L	4	of		8	Attorney Docket N	lumber	ICI 102				_
		<u>.</u>				ON PATENT LITER						
FH		D'USC 2):435 FRANG heart fi	CIO, et al., -41 (1997) CIS, "Cam ailure," <i>Cii</i>	II., "In vitro (2(Suppl 8) "Efects of). "parison of rculation 8: JERA, "A r	and in vivo studie: S98-S102 (1993 chronic ET _A -receneuroendocrine 2:1724-1729 (1993 eview of the dug	ptor blockade in ang activation in patients bo).	exapeptide endother itotensin II-induced with left ventricular	hen appropriate), title of the (s), volume-issue number of the control of the con	diovascul rtension 2 without co	29(1 Pt. ongestiv 1998).	е	
		GREEN 43(6):2	ER, "Mana NBAUM, e 584-2587	agement of it al., "Host (1983).	anorexia-cachex	cia associated with coonse to tumor in the	ancer and HIV infe	ction," Oncology 5(9):1 atin-treated mouse," C Heart J 58:190-203 (19)	3-17 (199 ancer Re	91).		
-++		L						. in vitro and in vivo,* J			 	$\frac{1}{4}$

		1			
Examiner's	3	11			\$
Signature	haaa	1	Date Considered		
Oigridad				1 8 1 7 2	ノ1の <i>に</i>
			<u> </u>		100

HEUSCH & DEUSSEN, "The effects of cardiac sympathetic nerve stimulation on perfusion of stenotic coronary arteries in

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

88:1805-1811 (1980).

the dog," Circ Res 53:8-15 (1983).

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Subst	Reduction Act of 1995, no persons are required to respond titute for form 1449A/PTO			
IN		C		- 1
		omplete if Known	TES Z	
, mm 2	TATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/807,558	4 2001 600/2900
2:1 2001 8		Filing Date	July 17, 2001	
F i	<i>.</i>	First Named Inventor	Stefan Dietmat Ank	,
S. S. S.		Group Art Unit	1614	
& TOADE	,	Examiner Name		
1001	5 of 8	Attorney Docket Number	ICI 102	
xaminer's Cite Initials* No.1	Include name of the author (item (book, magazine, journal,	NON PATENT LITERATURE DOCUMI (in CAPITAL LETTERS), title of the article (to l. serial, symposium, catalog, etc.), date, pag publisher, city and/or country where publisher	when appropriate), title of the ge(s), volume-issue number(s),	
	HUANG, et al., "Antialdosterone therapy in a 24(1):12-15 (1996). IHARA, et al., "In vitro biological profile of a receptor." J. Carriovasc Pharmod 20(Suppl	highly potent payol and obtain (ET)		1
	receptor," J Cardiovasc Pharmcol 20(Suppl. ISHIKAWA, et al., "Biochemical and pharma 788," Proc Natl Acad Sci USA 91:4892-4892 JAE, et al., "Pyrrolidine-3-carboxylic acids as Med Chem 40:3217-3227 (1997).	acological profile of a potent and select 2 (1994).	ctive endothelin B-receptor ant	tagonist, BQ-
	KALIMI, et al., "Effects of antimineralocortico 1):E737-9 (1990).			ŀ
	KICHUK, et al., "Angiotension-converting end failing explanted human hearts," Am J Cardio	0/60.13/A-142A (199/).		
1	KIM, et al., "Evaluation of RU28318 and RU4 antagonists, respectively: receptor measure	10555 as selective mineralocorticoid r s and functional studies," J Steroid Bi	eceptor and glucocorticold recoording to the control of the contro	æptor (1998).
	LEY, et al., "Sex- and menopause-associated		<u> </u>	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Examiner's

Signature

96

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of Translation is attached.

			ign (+) inside this box →		. Patent a	Approved for use the and Trademark Office: U.S.	TOUSE/08A (10-9) TOUSH 10/31 PM 0651-003 DEPARTMENT OF COMMERCE
1	0.00.0	Subel	titute for form 1449	, no persons are required to respond to	to a collection of information unless it contains a valid OMB	3 control number	
					<u> </u>	ete if Known	11 2 L
6	P E]	C) 61	TATEMENT	ON DISCLOSURE FBY APPLICANT	Application Number	09/807,558	1, 2001 1, 2001
` 327	7 1	띯	(use as many s	sheets as necessary).	•		8 0
\	1	K /			Filing Date	July 17, 2001	
12x	1 4	4			First Named Inventor	Stefan Dietmat	Anker
CM	RATRAIR	/			Group Art Unit	1614	Alkei
					Examiner Name		
E	Sheet		6 of	8	Attorney Docket Number	ICI 102	
r							
ŀ	Examiner's	T Cita	· · · · · · · · · · · · · · · · · · ·	OTHER ART - N	NON PATENT LITERATURE DOCUMENTS	,	
	Initials*	No.1		Include name of the author (i item (book, magazine, journal, or	(in CAPITAL LETTERS), title of the article (when a serial, symposium, catalog, etc.), date, page(s), wo publisher, city and/or country where published	appropriate), title of the volume-issue number(s),	
	FH.		3-11-01-01-01	rolldine-3-carboxylic acids as 61546)," <i>J Med Chem</i> 41:326	s endothelin antagonists. 3. Discovery of a period of the control		j 1
					•		n ET _A and ET _B
			MCDONALD, et :	al., "Plasma-catecholamine	es after cardiac infarction," Lancet 2:1021-10	023 (1969).	
ľ			MIHARA, et al., *	Binding characterization of	[3H]S-0139, an antagonist of the endothelin	n ET _A receptor subtyr	pe." Eur J

\bigvee	OHSHITA, et al., "Effects of selective inhibition of cathepsin B and general inhibition of cysteine proteinases on lysosomal proteolysis in rat liver in vivo and in vitro," N Eur J Biochem 209(1):223-31 (1992).							
Examiner's Signature	for It and Date Considered 6/7,2/26							

MIYATA, et al., "WS-7338, New endothelin receptor antagonists isolated from Streptomyces sp. No. 7338. II. Biological

MUELLER & AYRES, "Propranolol decreases sympathetic nervous activity reflected by plasma catecholamines during

NAMBI, et al., "Nonpeptide endothelin receptor antagonists. 1. Effects on binding and signal transduction on human

NYCANDER, et al., "Two-step mechanism of inhibition of cathespin B by cystatin C due to displacement of the proteinase

MUELLER, et al., "Cardiac catecholamine response during evolving myocardial infarct in man," Circulation 62(Suppl III):III-

characterization and pharmacological characterization of WS-7338 B,* J Antibiot (Tokyo) 45(1):83-7 (1992).

evolution of myocardial infarction in man," J Clin Invest 65:338-346 (1980).

occluding loop," FEBS Lett 422:61-64 (1998).

endothelin, and endothelin, receptors, J Pharmacol Exp Ther 271(2):755-61 (1994).

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents, ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language

Please type	e plus si	gn (+) inside this box →	•		Approved for use through 10 Patent and Trademark Office: U.S. DEPART	O/SI O/SI OM	3/08A (10 B 0651-0
Under the P	aperwork	Reduction Act of 1995,	no persons are required to respond t	o a collection of Information unless it contains	t a valid ONB control out-base	_	כח
	Subst	itute for form 1449	A/PTO		o vaso Cimb control increase	<u> </u>	<u>~</u>
					CENTER	24	
PE		ATEMENT	N DISCLOSURE BY APPLICANT heets as necessary)	Application Number	09/807,558	1600/2900	2001
f	į			Filing Date	July 17, 2001	_ දි	
	3	/		First Named Inventor	Stefan Dietmat Anker		
ENT & TRA				Group Art Unit	1614		
				Examiner Name	1014		
Sheet	<u>L</u>	7 of	8	Attorney Docket Number	ICI 102		
Examiner's Initials*	s Cite No.1		Include name of the author (item (book, magazine, journal, o	ION PATENT LITERATURE DOC in CAPITAL LETTERS), title of the arti- serial, symposium, catalog, etc.), date ublisher, city and/or country where put	cle (when appropriate), title of the , page(s), volume-issue number(s),		T
		00,, 02,0,0,	eurohormonal hypothesis: 20:248-254 (1992).	a theory to explain the mechanis	m of disease progression in heart fal	-	+
		PIEPOLI, et al., patients with chro	Contribution of muscle affe onic heart failure," Circulation	rents to the hemodynamic, auton on 93(5):940-952 (1996).	omic and ventilatory responses to ex	ercise in	+
		POMIKOWSKI, e imbalance in chro	t al., "Augmented periphera onic heart failure," Circulation	al chemosensitivity as a potential on 96(8):2586-2594 (1997).	input to baroreflex impairment and a	utonomic	-
		RAHMAN, et al.,	"Angiotensin II and aldoste	erone have opposite effects on m	agnesium excretion in man," Scot Me	ed. J.	-

REMES, "Neuroendocrine activity in untreated heart failure," Br Heart J 65:249-255 (1991).

the development of heart failure," J Heart Lung Transplant 16(10):1026-1034 (1997).

cerebral vasospasm," J Pharmacol Exp Ther 283(3):1110-18 (1997).

V	SIGURDSSON, et al., "Short- and long-term neurohormonal activation following acute myocardial infarction," Am Heart J 126:1068-1076 (1993).								
Examiner's Signature	Fine Italy Date Considered 6/22/06								

ROUX, et al., "Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental

SAKAKI, et al., "Discovery of IRL 3461: A novel and potent endothelin antagonist with balanced ET_A/ET_B affinity," Bioorg

SHEN, et al., "Defective endogenous nitric oxide-mediated modulation of cellular respiration in canine skeletal muscle after

SIGGERS, et al., "Serial plasma adrenaline and noradrenaline levels in myocardial infarction using a new double isotope

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

37:157-158 (1992).

Med Chem Lett 8(16):2241-6 (1998).

technique," 33:878-883 (1971).

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language

		(+) inside this box -				Approved for use through Patent and Trademark Office: U.S. DEP.	artment os ci
Under the Paperwork Reduction Act of 1995, no persons are required to respond to Substitute for form 1449A/PTO				to respond to	a collection of information unless it contain	is a valid OMB control number	<u>E</u>
	7				Complete if Known		TER
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				CANT	Application Number	09/807,558	1600/2900
i	,	(======,		• 37	Filing Date	July 17, 2001	
15.	ANGAKAK.				First Named Inventor	Stefan Dietmat Ani	
RADEMA					Group Art Unit	1614	er
					Examiner Name		
Sheet	8	of	8		Attorney Docket Number	ICI 102	
Examiner's	Cite		OTHER	RART - N	ON PATENT LITERATURE DO	CUMENTS	
Initials*	No.¹		nom (book, mayazı	nie, journai, o	UUISHRI. CIIV RANIAR COHNIN Where or	e, page(s), volume-issue number(s),	
54			, O,, O,,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	21).2202-2206 (1998).	conventionally treated patients with lin-A-receptor antagonists," J Med	
		The SOLVD Inve	,, _, ,	of enaland	il on survival in nations with mod	uced left ventricular ejection fractio	
						thepsin B, in vivo," N. FEBS Lett 20	
	0	TSCHESCHE, "6 1998).	Bimolecular interac	ction of ma	trix metalloproteinases and thei	r inhibitors," J Protein Chem 17(6):	549-51
	(URK, et al., "Ide 1995).	entification of bovin	ne stefin A	, a novel protein inhibitor of cysl	eine proteinases," FEBS Lett 360:	101-105
		/ETTER, et al., "	'Initial metabolic ar	nd hormor	nal response to acute myocardia	I infarction," Lancet 1:284-289 (197	74) .
	. V	VEINDEL, et al., n vitro," <i>Arzneimi</i>	*Inhibitory effects ittelforschung 41(9	of the nov 9):946-9 (1	rel anti-aldosterone compound (mespirenone on adrenocortical ste	roidogenesis
	2 9	HANG, et al., "A 5(1):176-182 (19	CE inhibitors pron 997).	note nitric	oxide accumulation to modulate	myocardial oxygen consumption,"	Circulation

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

06

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.